Novartis spending $342m to expand S'pore plant by 2026

Swiss biopharmaceutical manufacturing plant will create 100 high-skilled new jobs

- Rosalind Ang

Swiss pharmaceutical giant Novartis is spending US$256 million (S$342.3 million) to expand its biopharmaceutical manufacturing plant here.

The enlarged facility is expected to be operational by early 2026 and will focus on manufacturing therapeutic antibody drugs to address conditions like skin and respiratory diseases.

Digital and automation solutions will be used to lift productivity at the plant and improve operational efficiency.

The facility now produces 140 batches a year, equivalent to nine million finished doses. The expanded plant will more than double that output.

Novartis will also upskill its workforce through training programmes lasting around one to two years.